UTI의 흔한 원인균_APN의 치료_ESBL producing Enterobacteriacae의 치료 발표자료

소개

안녕하세요.
현역의사입니다. 의대생 때 발표했던 UTI의 흔한 원인균_APN의 치료_ESBL producing Enterobacteriacae의 치료 감염내과 발표 자료입니다.

의학 용이기도 하지만 간호학 용 또는 미래 의대생을 꿈꾸는 학생들 참고로도 사용가능할 것 같습니다.

도움이 되었으면 좋겠습니다. 감사합니다.

목차

#1. UTI의 흔한 원인균
#2. APN의 치료
#3. ESBL producing Enterobacteriacae의 치료

본문내용

# Escherichia coli는 급성 복합 요로 감염 (UTI)의 가장 M/C한 원인
# 다른 원인균으로는 Enterobacteriaceae (Klebsiella spp와 Proteus spp), Pseudomonas, enterococci, staphylococci (methicillin-sensitive Staphylococcus aureus [MSSA]와 methicillin-resistant S. aureus [MRSA])가있음.
# 특정 병원균의 유행은 부분적으로 host에 달려있음.
ex1) Pseudomonas는 health care를 많이 받는 환자에게 더 흔함.
ex2) Staphylococcus saprophyticus는 젊거나 건강한 여성에서 종종 APN의 원인이기도 함.

<Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007; 45:273.>
<Nicolle LE. A practical guide to antimicrobial management of complicated urinary tract infection. Drugs Aging 2001; 18:243.>

참고자료

· Arne S. et al. Risk Factors for Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Enterobacteriaceae –A Case–Control Study in a Low Prevalence Country
· PLoS ONE 8(7):e69581 · July 2013 with 153 
· Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007; 45:273
· Nicolle LE. A practical guide to antimicrobial management of complicated urinary tract infection. Drugs Aging 2001; 18:243.
· Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol 2013; 34:940.
· Harrison 19th ed
· 요로 감염 임상진료지침 권고안: 무증상 세균뇨, 단순 요로감염, 복잡성 요로감염, 세균성 전립선염 대한감염학회·대한화학요법학회·대한요로생식기감염학회·대한임상미생물학회
· Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J, Church DA. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 2000;283:1583-90
· Levasseur P, Girard AM, Miossec C, et al. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases. Antimicrob Agents Chemother 2015; 59:1931
· Farrell DJ, et al. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57:6305
· Harris PN, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 2015; 15:475.